Article Information
History
- May 16, 2023.
Article Versions
- You are currently viewing Version 1 of this article (May 16, 2023 - 13:49).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mei Yang1,*,
- Yuhan Liu2,3,*,
- Yi-Ching Hsueh3,
- Qiangzu Zhang3,
- Yanhui Fan2,3,
- Juntao Xu3,
- Min Huang3,
- Xu Li3,5,
- Guangming Tan5,6,
- Chunming Zhang5,6,
- Jianfei Yang4 and
- Gang Niu2,3,5,^
- 1Department of Breast Cancer, Cancer Centre, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
- 2Joint Turing-Darwin Laboratory of Phil Rivers Technology Ltd. and Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China
- 3Department of Computational Biology, Phil Rivers Technology Ltd, Beijing, China
- 4Department of Drug Discovery, Phil Rivers Technology Ltd, Beijing, China
- 5West Institute of Computing Technology, Chinese Academy of Sciences, Chongqing, China
- 6Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China
- ↵^Correspondence and requests for materials should be addressed to Dr. Gang Niu via g.niu{at}philrivers.com
↵* These authors equally contribute to this work
Posted May 16, 2023.
AI-based Model CRM to Evaluate the Responses of Breast Cancer Patients to CDK4/6 Inhibitors-Based Therapies and Simulate Real-World Clinical Trials
